A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
A [18]F-PSMA-1007 PET/CT or PET/MRI scan are nuclear medicine tests used to create pictures
of the whole body that may show where cells that express Prostate-Specific Membrane Antigen
(PSMA) are found. PSMA is a transmembrane protein that is overexpressed in the majority of
prostate cancers. PSMA imaging utilizes this overexpression, by binding on the transmembrane
receptor and internalization in the cancer cells. The internalized isotope can then be imaged
with the use of a PET/CT or PET/MRI scanner and show where cancer cells may be present in the
body. This imaging modality has been shown to be superior to conventional imaging, such as
bone scan and CT, in the detection of prostate cancer tumors.
The purpose of this study is to: 1) assess the clinical impact of a [18]F-PSMA-1007 scan on
patient management plans; 2) assess the diagnostic effectiveness of a [18]F-PSMA-1007 scan in
participants with known or suspected metastatic prostate cancer, as compared to standard of
care CT chest, abdomen, pelvis and bone scan; 3) evaluate the safety of [18]F-PSMA-1007; and
4) assess potential correlations of PSMA level of uptake in certain tumors with cancer
biologic markers such as PSA and Gleason score.